Aratana Therapeutics Inc (PETX) CEO Peter Steven St Sells 19,367 Shares

Aratana Therapeutics Inc (NASDAQ:PETX) CEO Peter Steven St sold 19,367 shares of Aratana Therapeutics stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $4.77, for a total transaction of $92,380.59. Following the transaction, the chief executive officer now directly owns 672,259 shares in the company, valued at $3,206,675.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Peter Steven St also recently made the following trade(s):

  • On Friday, November 10th, Peter Steven St sold 50,000 shares of Aratana Therapeutics stock. The stock was sold at an average price of $7.00, for a total transaction of $350,000.00.

Shares of Aratana Therapeutics Inc (PETX) traded up $0.04 during trading hours on Thursday, hitting $4.67. 202,358 shares of the company were exchanged, compared to its average volume of 554,707. Aratana Therapeutics Inc has a fifty-two week low of $4.53 and a fifty-two week high of $8.04. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $208.12, a price-to-earnings ratio of -3.21 and a beta of 3.37.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The business had revenue of $6.16 million for the quarter, compared to analyst estimates of $6.47 million. During the same period last year, the business posted ($0.38) earnings per share. The firm’s quarterly revenue was up 1440.0% on a year-over-year basis. equities analysts predict that Aratana Therapeutics Inc will post -1.03 earnings per share for the current year.

Large investors have recently modified their holdings of the stock. AWM Investment Company Inc. raised its holdings in shares of Aratana Therapeutics by 49.4% during the second quarter. AWM Investment Company Inc. now owns 1,587,620 shares of the biopharmaceutical company’s stock worth $11,478,000 after acquiring an additional 525,000 shares during the period. Teachers Advisors LLC raised its holdings in shares of Aratana Therapeutics by 34.5% during the second quarter. Teachers Advisors LLC now owns 72,244 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 18,526 shares during the period. Williams Jones & Associates LLC acquired a new stake in shares of Aratana Therapeutics during the second quarter worth $827,000. Grandeur Peak Global Advisors LLC raised its holdings in shares of Aratana Therapeutics by 40.4% during the second quarter. Grandeur Peak Global Advisors LLC now owns 538,363 shares of the biopharmaceutical company’s stock worth $3,892,000 after acquiring an additional 155,000 shares during the period. Finally, Broadfin Capital LLC raised its holdings in shares of Aratana Therapeutics by 40.3% during the second quarter. Broadfin Capital LLC now owns 5,184,942 shares of the biopharmaceutical company’s stock worth $37,487,000 after acquiring an additional 1,489,500 shares during the period. Institutional investors and hedge funds own 73.74% of the company’s stock.

A number of equities analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 18th. ValuEngine cut shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Jefferies Group set a $9.00 price target on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research report on Thursday, November 16th. HC Wainwright set a $10.00 price target on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 21st. Finally, Stifel Nicolaus reissued a “hold” rating and set a $6.00 price target on shares of Aratana Therapeutics in a research report on Monday, December 18th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Aratana Therapeutics has a consensus rating of “Hold” and an average price target of $8.55.

WARNING: “Aratana Therapeutics Inc (PETX) CEO Peter Steven St Sells 19,367 Shares” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/01/aratana-therapeutics-inc-petx-ceo-peter-steven-st-sells-19367-shares.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply